2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)

PHASE3TerminatedINTERVENTIONAL
Enrollment

297

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

June 1, 2018

Study Completion Date

June 1, 2018

Conditions
Alzheimer's Disease
Interventions
DRUG

Azeliragon 5mg

Trial Locations (71)

10032

New York

10312

Staten Island

11042

Lake Success

12208

Albany

18705

Plains

21208

Baltimore

27157

Winston-Salem

27607

Raleigh

28270

Charlotte

28401

Wilmington

31909

Columbus

32162

The Villages

32216

Jacksonville

32806

Orlando

33009

Hallandale

33014

Miami Lakes

33016

Hialeah

33122

Miami

33137

Miami

33140

Miami Beach

33351

Sunrise

33445

Delray Beach

33449

Lake Worth

33462

Atlantis

34243

Sarasota

38018

Cordova

39401

Hattiesburg

40504

Lexington

44122

Shaker Heights

44718

Canton

60640

Chicago

63141

Creve Coeur

St Louis

66205

Fairway

73103

Oklahoma City

73118

Oklahoma City

75231

Dallas

76309

Wichita Falls

78229

San Antonio

78232

San Antonio

84123

Murray

85004

Phoenix

85013

Phoenix

85724

Tucson

87109

Albuquerque

90706

Bellflower

90806

Long Beach

91206

Glendale

92251

Imperial

92408

San Bernardino

92506

Riverside

92614

Irvine

92626

Costa Mesa

92653

Laguna Hills

92705

Santa Ana

92835

Fullerton

97210

Portland

97225

Portland

98033

Kirkland

02459

Newton

02360

Plymouth

02169

Quincy

08540

Princeton

02914

East Providence

02916

East Providence

T2N 4Z6

Calgary

T1B 4E7

Medicine Hat

N7L 1C1

Chatham

M3B 2S7

Toronto

J8T 8J1

Gatineau

J4V 2J2

Greenfield Park

Sponsors

Lead Sponsor

All Listed Sponsors
lead

vTv Therapeutics

INDUSTRY